Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.727
Index Copernicus  – 166.39 pts
MNiSW – 40 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2019, vol. 28, nr 10, October, p. 1351–1358

doi: 10.17219/acem/104527

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Treatment of heart failure in the elderly in Poland. The results of the Polish part of EURObservational Research Programme: The Heart Failure Pilot Survey

Adam Rafał Poliwczak1,A,B,C,D,F, Janusz Śmigielski2,B,C,E, Agnieszka Bała3,B,D, Ewa Straburzyńska-Migaj4,B,E, Agata Tymińska5,B,C, Paweł Balsam5,A,B, Krzysztof Ozierański5,B,C, Agnieszka Kapłon-Cieślicka5,B,E, Joanna Zaprutko6,B,C, Jarosław Drożdż7,A,B,E,F

1 Department of Human Physiology, Medical University of Lodz, Poland

2 State Higher Vocational School of Konin, Poland

3 Department of Internal Diseases and Clinical Pharmacology, Medical University of Lodz, Poland

4 1st Department of Cardiology, Poznan University of Medical Sciences, Poland

5 1st Chair and Department of Cardiology, Medical University of Warsaw, Poland

6 2nd Department of Cardiology, Poznan University of Medical Sciences, Poland

7 Department of Cardiology, Medical University of Lodz, Poland

Abstract

Background. Pharmacotherapy remains the fundamental method of treating heart failure (HF). Treatment of the elderly is less based on the principles of evidence-based medicine (EBM) and doses do not reach the prescribed value.
Objectives. The aim of the study was to identify any distinct treatment of HF in the elderly compared to those under 65 years of age.
Material and Methods. This study describes the Polish part of the EURObservational Research Programme: The Heart Failure Pilot Survey (ESC-HF Pilot). Eligibility to the program was limited to people with HF in 26 centers in Poland. After the first phase, more data was collected at 3 and 12 months. It covered a total of 893 people.
Results. Treatment of HF is conducted largely in accordance with the applicable guidelines. The percentage of people over 65 years of age who use angiotensin-converting-enzyme inhibitors/angiotensin-II receptor blockers (ACE-I/ARB), β-blockers and mineralocorticoid-antagonists remains high. Also, during the 12-month follow-up the frequency of the use of β-blockers did not decrease, and a decrease in the number subjects treated with ACE-I was compensated by increasing percentage of the use of ARB. A major problem also seems to be the appropriate treatment to prevent thromboembolic complications in the case of coexistence of atrial fibrillation (AF). There is a large group of older people who do not receive proper anticoagulation.
Conclusion. The study showed the existence of differences in the treatment of HF in the elderly. It partly does not proceed in accordance with the guidelines, especially in the presence of multiple comorbidities.

Key words

pharmacotherapy, elderly, heart failure treatment

References (40)

  1. Dickstein K, Cohen-Solal A, Filippatos G, et al; ESC Committee for Practice Guidelines (CPG). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail. 2008;10(10):933–989.
  2. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in the Adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119(14):e391–479. doi:10.1161/CIRCULATIONAHA.109.192065
  3. Ponikowski P, Voors AA, Anker SD, et al; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–2200.
  4. Manzano L, Escobar C, Cleland JG, Flather M. Diagnosis of elderly patients with heart failure. Eur J Heart Fail. 2012;14(10):1097–1103.
  5. van Riet EE, Hoes AW, Limburg A, Landman MA, van der Hoeven H, Rutten FH. Prevalence of unrecognized heart failure in older persons with shortness of breath on exertion. Eur J Heart Fail. 2014;16(7):772–777. doi:10.1002/ejhf.110
  6. Díez-Villanueva P, Alfonso F. Heart failure in the elderly. J Geriatr Cardiol. 2016;13:115−117. doi:10.11909/j.issn.1671-5411.2016.02.009
  7. Jha SR, Ha HS, Hickman LD, et al. Frailty in advanced heart failure: A systematic review. Heart Fail Rev. 2015;20:553–560. doi:10.1007/s10741-015-9493-8
  8. Metra M, Cotter G, El-Khorazaty J, et al. Acute heart failure in the elderly: Differences in clinical characteristics, outcomes, and prognostic factors in the VERITAS Study. J Card Fail. 2015;21:179–188. doi:10.1016/j.cardfail.2014.12.012
  9. Mahjoub H, Rusinaru D, Soulière V, Durier C, Peltier M, Tribouilloy C. Long-term survival in patients older than 80 years hospitalized for heart failure. A 5-year prospective study. Eur J Heart Fail. 2008;10(1):78–84.
  10. Cherubini A, Oristrell J, Pla X, et al. The persistent exclusion of older patients from ongoing clinical trials regarding heart failure. Arch Intern Med. 2011;171(6):550–556. doi:10.1001/archinternmed.2011.31
  11. Flather MD, Shibata MC, Coats AJ, et al; SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure. Eur Heart J. 2005;26(3):215–225.
  12. Gustafsson F, Torp-Pedersen C, Seibaek M, Burchardt H, Kober L; DIAMOND study group. Effect of age on short and long-term mortality in patients admitted to hospital with congestive heart failure. Eur Heart J. 2004;25(19):1711–1717.
  13. Cohen-Solal A, Desnos M, Delahaye F, Emeriau JP, Hanania G. A national survey of heart failure in French hospitals. The Myocardiopathy and Heart Failure Working Group of the French Society of Cardiology, the National College of General Hospital Cardiologists and the French Geriatrics Society. Eur Heart J. 2000;21(9):763–769.
  14. Rywik TM, Kołodziej P, Targoński R, et al. Characteristics of the heart failure population in Poland: ZOPAN, a multicentre national programme. Kardiol Pol. 2011;69(1):24–31.
  15. Sztramko R, Chau V, Wong R. Adverse drug events and associated factors in heart failure therapy among the very elderly. Can Geriatr J. 2011;14(4):79–92.
  16. Zaprutko J, Michalak M, Nowicka A, et al. Hospitalization length and prognosis in heart failure patients. Kardiol Pol. 2017;75(4):519–526. doi:10.5603/KP.a2017.0088
  17. Maggioni AP, Dahlström U, Filippatos G, et al; Heart Failure Association of ESC (HFA). EURObservational Research Programme: The Heart Failure Pilot Survey (ESC-HF Pilot). Eur Heart J. 2010;31:1023–1031.
  18. McMurray JJ, Adamopoulos S, Anker SD, et al; ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33(14):1787–1847.
  19. Komajda M, Hanon O, Hochadel M, et al. Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II. Eur Heart J. 2009;30(4):478–486.
  20. Zieliński T, Kurjata P, Korewicki J; participants of POLKARD-HF. Prognosis in patients with severe heart failure referred for heart transplantation-POLKARD-HF 2003–2007. Int J Cardiol. 2010;145(2):242–244.
  21. Gokhale M, Girman C, Chen Y, Pate V, Funk MJ, Stürmer T. Comparison of diagnostic evaluations for cough among initiators of angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Pharmacoepidemiol Drug Saf. 2016;25(5):512–520. doi:10.1002/pds.3977
  22. Hallberg P, Nagy J, Karawajczyk M, et al. Comparison of clinical factors between patients with angiotensin-converting enzyme inhibitor-induced angioedema and cough. Ann Pharmacother. 2017;51(4):293–300. doi:10.1177/1060028016682251
  23. Woo KS, Nicholls MG. High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese. Br J Clin Pharmacol. 1995;40(2):141–144.
  24. Rich MW. Pharmacotherapy of heart failure in the elderly: Adverse events. Heart Fail Rev. 2012;17(4–5):589–595.
  25. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation. 1999;100(23):2312–2318.
  26. Demers C, Mody A, Teo KK, McKelvie RS. ACE inhibitors in heart failure: What more do we need to know? Am J Cardiovasc Drugs. 2005;5(6):351–359.
  27. Dulin BR, Haas SJ, Abraham WT, Krum H. Do elderly systolic heart failure patients benefit from beta blockers to the same extent as the non-elderly? Meta-analysis of 12,000 patients in large-scale clinical trials. Am J Cardiol. 2005;95(7):896–898.
  28. Sin DD, McAlister FA. The effects of beta-blockers on morbidity and mortality in a population-based cohort of 11,942 elderly patients with heart failure. Am J Med. 2002;113(8):650–656.
  29. Pascual-Figal DA, Redondo B, Caro C, et al. Comparison of late mortality in hospitalized patients >70 years of age with systolic heart failure receiving beta blockers versus those not receiving beta blockers. Am J Cardiol. 2008;102(12):1711–1717. doi:10.1016/j.amjcard.2008.07.059
  30. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709–717.
  31. Pitt B, Remme W, Zannad F, et al; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309–1321.
  32. Krum H, Shi H, Pitt B, et al; EMPHASIS-HF Study Group. Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: Analysis of the EMPHASIS-HF study. Circ Heart Fail. 2013;6(4):711–718. doi:10.1161/CIRCHEARTFAILURE.112.000173
  33. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med. 2004;351(6):543–551.
  34. Eschalier R, McMurray JJ, Swedberg K, et al; EMPHASIS-HF Investigators. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: Analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). J Am Coll Cardiol. 2013;62(17):1585–1593. doi:10.1016/j.jacc.2013.04.086
  35. Zugck C, Franke J, Gelbrich G, et al. Implementation of pharmacotherapy guidelines in heart failure: Experience from the German Competence Network Heart Failure. Clin Res Cardiol. 2012;101(4):263–272.
  36. Cichocka-Radwan A, Lelonek M. Annual prognostic factors in chronic heart failure in patients over 80 years old. Kardiol Pol. 2017;75(2):164–173.
  37. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: A Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837–847.
  38. Fitzmaurice DA, Hobbs FD, Jowett S, et al. Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: Cluster randomized controlled trial. BMJ. 2007;335(7616):383.
  39. Schnabel RB, Yin X, Gona P, et al. 50-year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: A cohort study. Lancet. 2015;386(9989):154–162.
  40. Ozierański K, Balsam P, Tymińska A, et al. Heart failure in elderly patients: Differences in clinical characteristics and predictors of 1-year outcome in the Polish ESC-HF Long-Term Registry. Pol Arch Med Wewn. 2016;126(7–8):502–513.